Why the study?
Prognosticating a high-risk cohort susceptible to early cardiac mortality after TEER is pivotal for formulating effective therapeutic regimens in patients with secondary mitral regurgitation.
What baseline clinical factors predict 1-year cardiac mortality or need for cardiac replacement therapy in patients with chronic heart failure and secondary mitral regurgitation undergoing transcatheter edge-to-edge mitral valve repair?
What baseline clinical factors predict 1-year cardiac mortality or need for cardiac replacement therapy in patients with chronic heart failure and secondary mitral regurgitation undergoing transcatheter edge-to-edge mitral valve repair?
Answers are grounded in this paper and cite their sources.
A simple 3-variable pre-procedural risk score (prior heart failure admissions, IV inotrope use, and plasma BNP) effectively stratifies 1-year cardiac mortality risk after TEER for secondary mitral regurgitation, helping identify advanced heart failure patients who may require intensified follow-up or alternative cardiac replacement therapies.
Background: Transcatheter edge-to-edge mitral valve repair (TEER) has emerged as a viable approach to addressing substantial secondary mitral regurgitation. In the contemporary landscape where ultimate heart failure-specific therapies, such as cardiac replacement modalities, are available, prognosticating a high-risk cohort susceptible to early cardiac mortality post-TEER is pivotal for formulating an effective therapeutic regimen. Methods: Our study encompassed individuals with secondary mitral regurgitation and chronic heart failure enlisted in the multi-center (Optimized CathEter vAlvular iNtervention (OCEAN)-Mitral registry. We conducted an assessment of baseline variables associated with cardiac death within one year following TEER. Results: Amongst the 1517 patients (median age: 78 years, 899 males), 101 experienced cardiac mortality during the 1-year observation period after undergoing TEER. Notably, a history of heart failure-related admissions within the preceding year, utilization of intravenous inotropes, and elevated plasma B-type natriuretic peptide levels emerged as independent prognosticators for the primary outcome (p < 0.05 for all). Subsequently, we devised a novel risk-scoring system encompassing these variables, which significantly stratified the cumulative incidence of the 1-year primary outcome (16%, 8%, and 4%, p < 0.001). Conclusions: Our study culminated in the development of a new risk-scoring system aimed at predicting 1-year cardiac mortality post-TEER.
No takes yet. Share an insight, caveat, or question.
Imamura et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: